CA-TALKDESK-INC
14.7.2022 11:19:12 CEST | Business Wire | Press release
Talkdesk®, Inc ., a global cloud contact center leader for customer-obsessed companies, has been positioned as a Leader in the 2021 Frost Radar: European Contact Center as a Service (CCaaS) Market analysis.
The European CCaaS market comprises more than 150 vendors offering solutions to companies across a broad range of verticals. From that field of 150 vendors, Frost & Sullivan independently plotted the top 20 companies – based on consistent growth and a strong focus on innovation – for the Frost Radar analysis. The growth and innovation leaders met key criteria including longevity of their offering in Europe, consistent growth, and investments in transformative technologies like artificial intelligence.
According to the analysis, “Talkdesk is distinguished by the comprehensiveness and high standards of its solutions,” having “one of the highest market averages of spending in R&D.” The analysis also highlights that “Talkdesk has a culture and reputation for ‘white glove’ service throughout the entire customer lifecycle,” providing “various services that enable companies to unlock the value of contact center transformation.”
"The Talkdesk vision to offer breakthrough solutions to enhance CX is evidenced through a commitment to innovations,” said Ankita Singh, senior industry analyst, Frost & Sullivan. “The recent patents, product release frequencies, and innovations specific to omnichannel engagement, workforce engagement, and analytics offer a solid testimony of this. The continued focus on the geographical and operational expansion has helped Talkdesk gain a competitive edge and well-positioned it for future growth."
“Talkdesk continues to strengthen its Leader position worldwide, strategically expanding our global reach, bringing new innovations and AI-based capabilities to market, and helping many of Europe’s largest organizations solve often complex and industry-specific challenges,” said Tiago Paiva, chief executive officer, Talkdesk. “We’re committed to giving businesses a better way to elevate customer experiences and drive business value and growth through the contact center.”
Download a complimentary copy of the full 2021 Frost Radar™: European Contact Center as a Service Market analysis
Additional Resources
- See other recent Talkdesk awards and recognition
- Save the date for the Talkdesk 2022 Opentalk CX Summit , with events in London and Madrid
- Read the latest Talkdesk Research™ report Future of AI 2022: Progressing AI maturity in the contact center
Social Networks
- Talkdesk Community: https://www.talkdesk.com/customer-community
- Blog: https://www.talkdesk.com/blog/
- Twitter: https://twitter.com/Talkdesk
- LinkedIn: https://www.linkedin.com/company/talkdesk/
- Facebook: https://www.facebook.com/Talkdesk/
- Instagram: https://www.instagram.com/Talkdesk/
About Talkdesk
Talkdesk® is a global cloud contact center leader for customer-obsessed companies. Our automation-first customer experience solutions optimize our customers’ most critical customer service processes. Our speed of innovation, vertical expertise, and global footprint reflect our commitment to ensuring that businesses can deliver better experiences across any industry and through any channel, resulting in higher customer satisfaction and accelerated business outcomes.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005402/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom